Ubiquitination of E3 ligases: Self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms

Cell Death and Differentiation

Volumn 18, Issue 9, 2011, Pages 1393-1402

  De Bie, P ^a   Ciechanover, A ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

E3 ligase; proteasomal degradation; self ubiquitination; ubiquitin

Indexed keywords

CBL PROTEIN; DAXX PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; F BOX PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RING FINGER PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4;

CELL CYCLE; DROSOPHILA MELANOGASTER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; UBIQUITINATION;

ANIMALS; ENZYME ACTIVATION; HUMANS; HYDROLYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 80051733972     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.16     Document Type: Review

References (80)

1. Kee Y, Huibregtse JM. Regulation of catalytic activities of HECT ubiquitin ligases. Biochem Biophys Res Commun 2007; 354: 329-333. (Pubitemid 46161353)
2. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
3. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-CBL/SLI-1. Mol Cell 1999; 4: 1029-1040. (Pubitemid 30054908)
4. Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle. Curr Biol 2004; 14: R787-R796. (Pubitemid 39239354)
5. Debonneville C, Flores SY, Kamynina E, Plant PJ, Tauxe C, Thomas MA et al. Phosphorylation of NEDD4-2 by SGK1 regulates epithelial Na(+) channel cell surface expression. EMBO J 2001; 20: 7052-7059. (Pubitemid 34062297)
6. Honda R, Yasuda H. Association of p19(Arf) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999; 18: 22-27. (Pubitemid 29005019)
7. Ben-Saadon R, Zaaroor D, Ziv T, Ciechanover A. The polycomb protein RING1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 2006; 24: 701-711. (Pubitemid 44839211)
8. Cao R, Tsukada Y, Zhang Y. Role of BMI-1 and RING1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 20: 845-854. (Pubitemid 41814874)
9. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of Cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
10. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by NEDD8 conjugation. Mol Cell 2008; 32: 21-31.
11. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999; 96: 11364-11369. (Pubitemid 29487386)
12. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 1995; 92: 2563-2567.
13. Nuber U, Schwarz SE, Scheffner M. The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur J Biochem 1998; 254: 643-649. (Pubitemid 28308117)
14. Hu G, Fearon ER. SIAH-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol Cell Biol 1999; 19: 724-732. (Pubitemid 29018473)
15. Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G et al. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 2009; 16: 658-666.
16. Galan JM, Peter M. Ubiquitin-dependent degradation of multiple F-box proteins by an autocatalytic mechanism. Proc Natl Acad Sci USA 1999; 96: 9124-9129. (Pubitemid 29374718)
17. Gallagher E, Gao M, Liu YC, Karin M. Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci USA 2006; 103: 1717-1722. (Pubitemid 43228759)
18. Bruce MC, Kanelis V, Fouladkou F, Debonneville A, Staub O, Rotin D. Regulation of NEDD4-2 self-ubiquitination and stability by a PY motif located within its HECT-domain. Biochem J 2008; 415: 155-163.
19. Wiesner S, Ogunjimi AA, Wang HR, Rotin D, Sicheri F, Wrana JL et al. Autoinhibition of the HECT-type ubiquitin ligase SMURF2 through its C2 domain. Cell 2007; 130: 651-662. (Pubitemid 47268058)
20. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING fingerdependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-8951. (Pubitemid 30180252)
21. Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J Virol 2000; 74: 6408-6417. (Pubitemid 30429807)
22. Ryan PE, Davies GC, Nau MM, Lipkowitz S. Regulating the regulator: negative regulation of CBL ubiquitin ligases. Trends Biochem Sci 2006; 31: 79-88. (Pubitemid 43221840)
23. Petroski MD, Deshaies RJ. Function and regulation of Cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20. (Pubitemid 40064895)
24. Okamoto K, Taya Y, Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett 2009; 583: 2710-2714.
25. Coutts AS, Adams CJ, La Thangue NB. p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) 2009; 8: 483-490.
26. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12: 355-366. (Pubitemid 47539309)
27. Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein HDM2. Nat Cell Biol 2007; 9: 331-338. (Pubitemid 46344613)
28. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y et al. CBL-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 2001; 276: 27677-27684.
29. Zeng S, Xu Z, Lipkowitz S, Longley JB. Regulation of stem cell factor receptor signaling by CBL family proteins (CBL-b/c-CBL). Blood 2005; 105: 226-232. (Pubitemid 40053087)
30. Alwan HA, van Zoelen EJ, van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 2003; 278: 35781-35790. (Pubitemid 37102355)
31. Wang Y, Yeung YG, Langdon WY, Stanley ER. c-CBL is transiently tyrosinephosphorylated, ubiquitinated, and membrane-targeted following CSF-1 stimulation of macrophages. J Biol Chem 1996; 271: 17-20.
32. Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I et al. ALIX/AIP1 antagonizes epidermal growth factor receptor downregulation by the CBL-SETA/CIN85 complex. Mol Cell Biol 2004; 24: 8981-8993. (Pubitemid 39313903)
33. Lennartsson J, Wardega P, Engstrom U, Hellman U, Heldin CH. ALIX facilitates the interaction between c-CBL and platelet-derived growth factor beta-receptor and thereby modulates receptor down-regulation. J Biol Chem 2006; 281: 39152-39158. (Pubitemid 46041875)
34. Li Y, Gazdoiu S, Pan ZQ, Fuchs SY. Stability of homologue of Slimb F-box protein is regulated by availability of its substrate. J Biol Chem 2004; 279: 11074-11080. (Pubitemid 38401599)
35. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F et al. The F-box protein SKP2 is a ubiquitylation target of a CUL1-based core ubiquitin ligase complex: evidence for a role of CUL1 in the suppression of SKP2 expression in quiescent fibroblasts. EMBO J 2000; 19: 5362-5375.
36. Wang W, Ungermannova D, Jin J, Harper JW, Liu X. Negative regulation of SCFSKP2 ubiquitin ligase by TGF-b signaling. Oncogene 2004; 23: 1064-1075. (Pubitemid 38269960)
37. Listovsky T, Oren YS, Yudkovsky Y, Mahbubani HM, Weiss AM, Lebendiker M et al. Mammalian CDH1/FZR mediates its own degradation. EMBO J 2004; 23: 1619-1626. (Pubitemid 38579522)
38. Pashkova N, Gakhar L, Winistorfer SC, Yu L, Ramaswamy S, Piper RC. WD40 repeat propellers define a ubiquitin-binding domain that regulates turnover of F box proteins. Mol Cell 2010; 40: 433-443.
39. Bennett EJ, Rush J, Gygi SP, Harper JW. Dynamics of Cullin-RING ubiquitin ligase network revealed by systemic quantitative proteomics. Cell 2010; 143: 951-965.
40. Kamura T, Brower CS, Conaway RC, Conaway JW. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 2002; 277: 30388-30393.
41. Kamura T, Sato S, Haque D, Liu L, Kaelin Jr WG, Conaway RC et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 1998; 12: 3872-3881. (Pubitemid 29024849)
42. Zaaroor-Regev D, de Bie P, Scheffner M, Noy T, Shemer R, Heled M et al. Regulation of the polycomb protein RING1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc Natl Acad Sci USA 2010; 107: 6788-6793.
43. Herman-Bachinsky Y, Ryoo HD, Ciechanover A, Gonen H. Regulation of the Drosophila ubiquitin ligase DIAP1 is mediated via several distinct ubiquitin system pathways. Cell Death Differ 2007; 14: 861-871. (Pubitemid 46444523)
44. Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci USA 2005; 102: 16182-16187. (Pubitemid 41688888)
45. Ditzel M, Wilson R, Tenev T, Zachariou A, Paul A, Deas E et al. Degradation of Diap1 by the N-end rule pathway is essential for regulating apoptosis. Nat Cell Biol 2003; 5: 467-473. (Pubitemid 36592271)
46. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, GP78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci USA 2001; 98: 14422-14427. (Pubitemid 33121407)
47. Ballar P, Ors AU, Yang H, Fang S. Differential regulation of CFTRDeltaF508 degradation by ubiquitin ligases GP78 and HRD1. Int J Biochem Cell Biol 2010; 42: 167-173.
48. Shmueli A, Tsai YC, Yang M, Braun MA, Weissman AM. Targeting of GP78 for ubiquitinmediated proteasomal degradation by HRD1: cross-talk between E3s in the endoplasmic reticulum. Biochem Biophys Res Commun 2009; 390: 758-762.
49. Courbard JR, Fiore F, Adelaide J, Borg JP, Birnbaum D, Ollendorff V. Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBL-C and AIP4/ITCH. J Biol Chem 2002; 277: 45267-45275. (Pubitemid 36159132)
50. Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S et al. WW domain HECT E3s target CBL RING finger E3s for proteasomal degradation. J Biol Chem 2003; 278: 43169-43177. (Pubitemid 37345936)
51. Yang B, Gay DL, MacLeod MK, Cao X, Hala T, Sweezer EM et al. NEDD4 augments the adaptive immune response by promoting ubiquitin-mediated degradation of CBL-b in activated T cells. Nat Immunol 2008; 9: 1356-1363.
52. Gruber T, Hermann-Kleiter N, Hinterleitner R, Fresser F, Schneider R, Gastl G et al. PKC-y modulates the strength of T cell responses by targeting CBL-b for ubiquitination and degradation. Sci Signal 2009; 2: ra30.
53. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(SKP2-CKS1) ubiquitin ligase by the APC/C(CDH1) ubiquitin ligase. Nature 2004; 428: 190-193. (Pubitemid 38374316)
54. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin Jr WG. Degradation of the SCF component SKP2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 2004; 428: 194-198. (Pubitemid 38374317)
55. Benmaamar R, Pagano M. Involvement of the SCF complex in the control of CDH1 degradation in S-phase. Cell Cycle 2005; 4: 1230-1232. (Pubitemid 41365394)
56. Ayad NG, Rankin S, Murakami M, Jebanathirajah J, Gygi S, Kirschner MW. TOME-1, a trigger of mitotic entry, is degraded during G1 via the APC. Cell 2003; 113: 101-113. (Pubitemid 36411963)
57. Nilsson J, Yekezare M, Minshull J, Pines J. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol 2008; 10: 1411-1420.
58. Pfleger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by CDH1. Genes Dev 2000; 14: 655-665. (Pubitemid 30176820)
59. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M et al. Control of meiotic and mitotic progression by the F box protein b-TRCP1 in vivo. Dev Cell 2003; 4: 799-812. (Pubitemid 36676033)
60. Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD, Jackson PK. Prophase destruction of Emi1 by the SCF(b-TRCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell 2003; 4: 813-826. (Pubitemid 36676034)
61. Wu-Baer F, Lagrazon K, Yuan W, Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 2003; 278: 34743-34746. (Pubitemid 37102231)
62. Mallery DL, Vandenberg CJ, Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 2002; 21: 6755-6762. (Pubitemid 36014547)
63. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001; 276: 14537-14540.
64. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-351. (Pubitemid 32694385)
65. Baud V, Liu ZG, Bennett B, Suzuki N, Xia Y, Karin M. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev 1999; 13: 1297-1308. (Pubitemid 29250197)
66. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A et al. TAB2 and TAB3 activate the NF-kB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-548. (Pubitemid 39141781)
67. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N et al. The type I TGF-b receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008; 10: 1199-1207.
68. Fan Y, Yu Y, Shi Y, Sun W, Xie M, Ge N et al. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor a-and interleukin-1b-induced IKK/NF-kB and JNK/AP-1 activation. J Biol Chem 2010; 285: 5347-5360.
69. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461: 114-119.
70. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IkB kinase activation. J Biol Chem 2007; 282: 4102-4112. (Pubitemid 47084488)
71. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kB activation. Nat Cell Biol 2006; 8: 398-406.
72. Woelk T, Oldrini B, Maspero E, Confalonieri S, Cavallaro E, Di Fiore PP et al. Molecular mechanisms of coupled monoubiquitination. Nat Cell Biol 2006; 8: 1246-1254. (Pubitemid 44660589)
73. van Bergen En, Henegouwen PM. EPS15: a multifunctional adaptor protein regulating intracellular trafficking. Cell Commun Signal 2009; 7: 24.
74. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008; 90: 270-283. (Pubitemid 351187762)
75. de Bie P, Zaaroor-Regev D, Ciechanover A. Regulation of the polycomb protein RING1B ubiquitination by USP7. Biochem Biophys Res Commun 2010; 400: 389-395.
76. Nathan JA, Sengupta S, Wood SA, Admon A, Markson G, Sanderson C et al. The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X. Traffic 2008; 9: 1130-1145. (Pubitemid 351916888)
77. Maertens GN, El Messaoudi-Aubert S, Elderkin S, Hiom K, Peters G. Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. EMBO J 2010; 29: 2553-2565.
78. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
79. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C et al. The ubiquitinmodifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060. (Pubitemid 41057725)
80. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kB signalling. Nature 2004; 430: 694-699. (Pubitemid 39061687)